StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a report issued on Thursday morning. The brokerage issued a sell rating on the biotechnology company's stock.
Separately, Barclays decreased their target price on Cellectis from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Tuesday, November 5th.
View Our Latest Stock Analysis on CLLS
Cellectis Stock Performance
Shares of NASDAQ:CLLS opened at $1.91 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The business has a 50-day simple moving average of $1.99 and a two-hundred day simple moving average of $2.22. Cellectis has a fifty-two week low of $1.70 and a fifty-two week high of $3.77.
Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $18.05 million for the quarter, compared to analysts' expectations of $5.00 million. During the same period in the previous year, the firm earned ($0.31) earnings per share. Equities research analysts forecast that Cellectis will post -0.46 EPS for the current fiscal year.
Hedge Funds Weigh In On Cellectis
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLLS. XTX Topco Ltd purchased a new stake in shares of Cellectis during the 2nd quarter worth approximately $29,000. First Affirmative Financial Network bought a new stake in Cellectis in the third quarter worth $45,000. Principal Financial Group Inc. raised its stake in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock valued at $817,000 after purchasing an additional 12,467 shares in the last quarter. Finally, Long Focus Capital Management LLC lifted its position in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock valued at $8,634,000 after purchasing an additional 130,000 shares during the last quarter. 63.90% of the stock is owned by institutional investors.
About Cellectis
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Featured Stories
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
